Change of the nature of dystonic hyperkinesis in patients suffering from spasmodic torticollis following recurrent injections of botulotoxin A

Cover Page

Cite item

Full Text


The data of the 6-year follow-up of 101 patients with spasmodic torticollis (ST) receiving regular treatment with botulotoxin type A (BTA) in Belarus are presented. The comparison group comprised 74 patients suffering from ST and receiving traditional therapy without BTA. Stable positive effect of BTA on repeat injections every 6–10 months was revealed. On this background, the amount of combined forms of ST, as well as the number of cases of retro- and laterokollis, increased, and a part of the patients displayed the «bayonet» symptom. Change in the head posture required changes in the selection of target muscles for BTA injection. Clinical example of high efficacy of longterm therapy with 8 consecutive injections is presented. Even with long intervals (9–18 months) between repeat BTA injections, the degree of ST severity did not reach the initial values.


About the authors

S. A. Likhachev

Republican Research and Clinical Center of Neurology and Neurosurgery, the Ministry of Healthcare of the Republic of Belarus

Belarus, Minsk

T. N. Chernukha

Republican Scientific and Practical Center of Neurology and Neurosurgery of the Ministry of Health of Belarus

Author for correspondence.
Belarus, Minsk


  1. Лихачев С.А., Рушкевич Ю.Н., Веевник Е.В. и др. Фокальная мышечная дистония: этиология, патогенез, диагностика, лечение. Методическое пособие. Минск: Ольдевен, 2005.
  2. Орлова О.Р., Голубев В.П. Феномен инверсии ротации при спастической кривошее. Журн. неврол. и психиатрии им. С.С. Корсакова 1986; 3: 348–350.
  3. Орлова О.Р., Яхно Н.Н. Применение Ботокса (БТА) в клинической практике. М.: Каталог, 2000.
  4. Тимербаева С.Л. Ботулинестический токсин типа А (диспорт) – новое слово в клинической нейрофармакологии. Фарматека 2007; 17: 40–46.
  5. Шток В.Н., Иванова-Смоленская И.А., Левин О.С. (ред.) Экстрапирамидные расстройства: Руководство по диагностике и лечению. М.: МЕДпресссинформ, 2002.
  6. Albanese A. Update on dystonia. Teaching course 1.2. In: 10th Congress of the European Federation of Neurological Societies. Glasgow, Sept. 2–5, 2006: 1–17.
  7. Brin M.F., Hallett M., Jankovic J. Scientific and therapeutic aspects of botulinum toxic. N.Y.: Wilkins, 2002.
  8. Collaborative Group. The Epidemiological Study of Dystonia in Europe (ESDE). A prevalence study of primary dystonia in eight European countries. J. Neurol. 2000; 47: 787–792.
  9. Dressier D. Botulinum toxin therapy. Stuttgart: Thieme Verlag, 2000.
  10. Gelb D.J., Yoshimura D.M., Olney R.K. et al. Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann. Neurol. 1991; 29: 370–376.
  11. Haussermann P., Marczoch S., Klinger С. et al. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov. Disord. 2004; 19: 303–308.
  12. Homann C.N., Suppan K., Wenzel K. et al. East-west differences in the organization of botulinum toxin use in nine Central European countries. Eur. J. Neurol. 2003; 10: 213–219.
  13. Kessler K.R., Skutta M., Benecke R. Long-term treatment of cervical dystonia with botulinum toxin А: efficacy, safety and antibody frequency. J. Neurol. 1999; 6: 74–76.
  14. Zuber M., Sebald M., Bathien N. et al. Botulinum antibodies in distonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993; 43: 1715–1718.

Supplementary files

Supplementary Files

Copyright (c) 2008 Likhachev S.A., Chernukha T.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies